Wednesday, March 08, 2017 4:02:39 PM
In Reply to 'diddobuyer'
It could just be your body is getting into shape and have nothing to do with the supplement. I am in shape I started taking this and have not noticed anything.
To follow KarinCA, click here then click "Follow This Member" under my photo.
Be kinder than necessary, for everyone you meet is fighting some kind of battle.
Recent CDXC News
- ChromaDex Announces Tru Niagen® is Now Third-Party Verified Through the Alkemist Assured™ Transparency Program • Business Wire • 03/26/2024 12:32:00 PM
- ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2023 Results • Business Wire • 03/06/2024 09:04:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2024 09:02:29 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/06/2024 09:01:37 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/24/2024 02:00:40 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/24/2024 01:59:47 AM
- ChromaDex to Report Fourth Quarter 2023 Financial Results on Wednesday, March 6, 2024 • Business Wire • 02/21/2024 01:32:00 PM
- ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow on Monday, February 12, 2024 • Business Wire • 02/05/2024 01:32:00 PM
- ChromaDex to Present at the Lytham Partners 2024 Investor Select Conference • Business Wire • 01/26/2024 09:08:00 PM
- ChromaDex Supports the US Military with its Industry Leading NAD+ Supplement, Tru Niagen® • Business Wire • 12/20/2023 02:04:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/13/2023 09:00:16 PM
- Neurohacker Collective and ChromaDex Partner to Optimize Cellular Health with the Debut of Qualia NAD+ • PR Newswire (US) • 12/12/2023 03:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/04/2023 09:12:33 PM
- A Milestone Phase I Randomized, Double-Blind Clinical Trial Demonstrates High-Dose Niagen®, Patented Nicotinamide Riboside (NR), Supplementation Induces a Potent NAD+ Response and Is Associated With Mild Improvement in Parkinson's Disease (PD) • Business Wire • 11/30/2023 01:34:00 PM
- Newly Published Phase II Clinical Study Demonstrates that Supplementation with Niagen®, Patented Nicotinamide Riboside (NR), Elevates NAD+ Up to Fourfold, Improving Motor Coordination and Eye Movement in Ataxia Telangiectasia (AT) Patients • Business Wire • 11/15/2023 01:32:00 PM
- ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow on Tuesday, November 14, 2023 • Business Wire • 11/09/2023 01:32:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/08/2023 09:02:24 PM
- ChromaDex Corporation Reports Third Quarter 2023 Financial Results • Business Wire • 11/08/2023 09:02:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/08/2023 09:01:06 PM
- ChromaDex Debuts Clinical Strength Tru Niagen® Pro 1,000mg Featuring Niagen® (Patented Nicotinamide Riboside), One of the Most Efficient Nicotinamide Adenine Dinucleotide (NAD+) Boosters Available, to Consumers Nationwide • Business Wire • 11/01/2023 12:34:00 PM
- ChromaDex to Report Third Quarter 2023 Financial Results on Wednesday, November 8, 2023 • Business Wire • 10/31/2023 12:34:00 PM
- ChromaDex and Zesty Paws® Crack the Code on Cellular Health for Dogs With ‘Healthy Aging’ Line • Business Wire • 10/26/2023 12:32:00 PM
- A Milestone Clinical Study Reveals that Elevating Nicotinamide Adenine Dinucleotide (NAD+) with Nicotinamide Riboside (NR) Supplementation Effectively Reduces Inflammation in Both Healthy Subjects and Immune Cells Derived from Psoriasis Patients • Business Wire • 10/02/2023 12:32:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/07/2023 10:23:14 AM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 09/07/2023 10:20:26 AM
VPR Brands LP Reports Record Annual Financial Performance for Fiscal Year 2023 • VPRB • Apr 19, 2024 11:24 AM
Coinllectibles' Subsidiary, Grand Town Development Limited, Acquires Rare Song Dynasty Ceramics Worth Over USD28million • COSG • Apr 18, 2024 8:03 AM
ILUS Provides Form 10-K Filing Update • ILUS • Apr 17, 2024 9:54 AM
Glucotrack Announces Expansion of Its Continuous Glucose Monitoring Technology to Epidural Glucose Monitoring • GCTK • Apr 17, 2024 8:00 AM
Maybacks Global Entertainment To Fire Up 24 New Stations in Louisiana • AHRO • Apr 16, 2024 1:30 PM
Cannabix Technologies Begins Certification of Contactless Alcohol Breathalyzer, Re-Brands product series to Breath Logix • BLOZF • Apr 16, 2024 8:52 AM